Skip to content
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

Filings

Form TypeForm DescriptionFiling DateReport DateView Report
424B5Prospectus [Rule 424(b)(5)]2026-04-03
8-KCurrent report2026-04-032026-04-03
8-KCurrent report2026-04-032026-04-03
EFFECTNotice of Effectiveness2026-03-30
8-KCurrent report2026-03-302026-03-27
8-KCurrent report2026-03-232026-03-23
S-3Registration statement under Securities Act of 19332026-03-20
8-KCurrent report2026-03-092026-03-09
8-KCurrent report2026-03-062026-03-04
8-KCurrent report2026-02-122026-02-11
10-QQuarterly report [Sections 13 or 15(d)]2026-02-112025-12-31
SCHEDULE 13GForm - SCHEDULE 13G2026-01-20
4Statement of changes in beneficial ownership of securities2025-12-192025-12-19
4Statement of changes in beneficial ownership of securities2025-12-192025-12-19
4Statement of changes in beneficial ownership of securities2025-12-192025-12-19
4Statement of changes in beneficial ownership of securities2025-12-192025-12-19
4Statement of changes in beneficial ownership of securities2025-12-192025-12-19
4Statement of changes in beneficial ownership of securities2025-12-192025-12-19
4Statement of changes in beneficial ownership of securities2025-12-192025-12-19
8-KCurrent report2025-12-182025-12-17
4Statement of changes in beneficial ownership of securities2025-12-172025-12-15
4Statement of changes in beneficial ownership of securities2025-12-172025-12-15
4Statement of changes in beneficial ownership of securities2025-12-172025-12-15
8-KCurrent report2025-12-152025-12-12
S-8Securities to be offered to employees in employee benefit plans2025-12-08
8-KCurrent report2025-11-192025-11-18
10-QQuarterly report [Sections 13 or 15(d)]2025-11-062025-09-30
DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material2025-11-03
DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material2025-11-03
DEF 14AOther definitive proxy statements2025-11-032025-12-17
  • 1
  • 2
  • 3
  • …
  • 16
  • Next »

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono

#1445 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • Articles and Videos
  • Webinar: Alzheimer’s Outlook – Neuroinflammation, the Next Step
  • The Evolving Alzheimer’s Disease Landscape

© Copyright 2026 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*